Results 41 to 50 of about 5,939 (158)

REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY) [PDF]

Arquivos de Gastroenterologia
Background: Extraintestinal manifestations (EIMs) significantly impact patients with inflammatory bowel disease (IBD). Janus kinase inhibitors (JAKi) are emerging as a potential treatment.
Viviana PARRA-IZQUIERDO, Oscar ARDILA, Juan Ricardo MÁRQUEZ, Javier RIVEROS, Álvaro Andrés GÓMEZ-VENEGAS, Carlos Andrés MEDRANO-ALMANZA, Manuel BALLESTEROS, Jonathan BARRETO-PÉREZ, Juan Sebastian FRIAS-ORDOÑEZ   +8 more
doaj   +1 more source

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Clinical and Translational Science, 2022
Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA).
Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson, Mohamed‐Eslam F. Mohamed   +4 more
doaj   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Upadacitinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science
Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases ...
Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung   +4 more
doaj   +1 more source

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Drugs in Context, 2020
Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which ...
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, Branimir Anić, Matija Tomšič, Vadim Mazurov, Marija Maksimovic, Orsolya Nagy, Jerzy Świerkot, Tzvetanka Petranova, Tiina Veldi, Asta Baranauskaitė, Catalin Codreanu, Daina Andersone, Roy Fleischmann   +14 more
doaj   +1 more source

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

Rheumatology &Autoimmunity, EarlyView.
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai   +3 more
wiley   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient ...
Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg   +17 more
doaj   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Benzalkonium Chloride in Eye Drops Causing Allergic Contact Dermatitis: A Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT We present three patients who developed allergic contact dermatitis (ACD) from benzalkonium chloride (BAK) in ophthalmic drops. BAK is a preservative commonly found in ophthalmic formulations and there is a rising trend of ACD to this allergen. The irritant and sensitising properties of BAK on the ocular mucosa will be discussed.
Arav Kannen, Penelope Harrison, Elizabeth Christou   +2 more
wiley   +1 more source